134
Participants
Start Date
November 27, 2018
Primary Completion Date
August 1, 2025
Study Completion Date
August 1, 2025
mRNA-2752
Solution for intratumoral injection
Durvalumab
Solution for infusion after dilution
Westmead Hospital, Westmead
Alfred Health, Melbourne
One Clinical Research Perth, Nedlands
NYU Langone Medical Center, New York
Icahn School of Medicine at Mount Sinai, New York
James P. Wilmot Cancer Center, Rochester
Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota
Sarah Cannon Research Institute, Nashville
The Cleveland Clinic Foundation, Cleveland
Henry Ford Hospital, Detroit
The University of Chicago Medicine, Chicago
University of Colorado Denver, Aurora
Providence St. John's Health Center, Santa Monica
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Rambam Medical Center, Haifa
Rabin Medical Center, Petah Tikva
Chaim Sheba Medical Center, Ramat Gan
Tel Aviv Sourasky Medical Center, Tel Aviv
Yale Cancer Center, New Haven
Massachusetts General Hospital, Boston
Cancer Center at Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Oregon Health and Science University, Portland
Melanoma Institute of Australia, Wollstonecraft
Collaborators (1)
AstraZeneca
INDUSTRY
ModernaTX, Inc.
INDUSTRY